Ligand Pharmac-B

Forecast & Rating10 analysts currently cover Ligand Pharmac-B, with about 90.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $323.30, about 12.3% upside from the current price of $288.01. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 49.0% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Ligand Pharmac-B closely still see room for the stock to rise. Data as of Jul 21, 2026; for reference only and not investment advice.